The level of selling is minimal relative to company size and appears routine; no material negative signal is evident. Traders should monitor for further selling patterns, especially among C-suite executives, but this cluster alone does not suggest urgency or distress.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $88.53entry
- T+1 · 7mo ago +1.51%α +0.29% · $89.87
- T+5 · 7mo ago −1.81%α −5.10% · $86.93
- T+20 · 6mo ago −5.00%α −12.76% · $84.10
- T+60 · 4mo ago +34.42%α +24.86% · $119.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two corporate insiders at Kymera Therapeutics sold shares in the past week, including Director Booth Bruce selling 4,159 shares for $374,185 and Chief Business Officer Noah Goodman selling 2,000 shares for $174,700. The total open-market sales amount to $549,000, representing 0.0075% of the company's $7.3B market cap. Most transactions were non-cash derivative exercises with no economic impact.
Key Financial Metrics
Key Facts
- Director Booth Bruce sold 4,159 shares for $374,185 on 2026-04-14 and also exercised 10,518 derivative shares (non-cash) across multiple transactions.
- Chief Business Officer Noah Goodman sold 2,000 shares for $174,700 on 2026-04-10.
- Total open-market sales in the cluster: $549,000.
- Total value represents 0.0075% of Kymera's $7.3B market cap.
- Multiple derivative exercises and tax-related transactions (codes M, F) are non-cash events with no direct financial impact.
Financial Impact
$549,000 in open-market sales (0.0075% of market cap)
Risk Factors
- Continued insider selling could erode confidence if volume increases.
- Non-cash derivative exercises may signal upcoming selling pressure if shares are now held outright.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KYMR-1776377848802 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers